Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

This study found that finasteride treatment improved cardiac function and reduced heart failure progression in mice, suggesting it could be a potential therapy for pathological cardiac hypertrophy and dysfunction.

This review discusses the use of finasteride and alpha antagonists for symptomatic benign prostatic hypertrophy and suggests current studies are evaluating combination therapies as potential non-surgical alternatives.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

This study found that use of 5-alpha reductase inhibitors for benign prostatic hyperplasia was not associated with an increased risk of hip fracture in men.

In this study, anti-androgenic therapy with finasteride for prostate disease was associated with reduced cardiac hypertrophy in heart failure patients, encouraging further investigation in larger cohorts.

In this study, the researchers did not confirm previously reported links between AGA and smoking or benign prostatic hypertrophy, but found potential associations with alcohol consumption and lean body mass at age 21 that merit further investigation.

This review discusses the use of antiandrogens for various conditions like prostate cancer and highlights their potential benefits in remission rates and symptom improvement, but it reports no new clinical results.

This study demonstrated that finasteride treatment reduced cardiac dysfunction and hypertrophic remodeling in mice after myocardial infarction, suggesting potential as a therapeutic strategy for heart failure.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study found that the compound 9,11-dehydrocortexolone 17alpha-butyrate (CB-03-04) showed strong local antiandrogenic activity in animal models, suggesting potential for treating prostate conditions.

This study suggests that the use of 5α-reductase inhibitors in men may be associated with macular abnormalities, characterized by cystoid changes and foveal cavitation, potentially progressing to more severe defects.

This study suggests that the use of tamsulosin may worsen sleep-disordered breathing in some patients with obstructive sleep apnea being treated with CPAP.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This article proposes that androgenic alopecia might be an evolutionary mechanism for reducing prostate cancer risk by enhancing UV absorption, rather than being a risk factor.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This article discusses the role of dihydrotestosterone in human prostatic adenocarcinoma growth and suggests that 6-methyleneprogesterone could be used to inhibit DHT for treating hormone-responsive prostate cancer, without new clinical findings.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.